NCT00518427View on ClinicalTrials.gov

Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions

Diabetes Type 2

Interventions

DRUG

Insulin Glargine

"Lantus (insulin glargine \[rDNA origin\] injection), individual dosing , subcutaneous injection, 100 IU/ml.~Duration of treatment will be judge by the investigator. Last QoL assessed in the study will be 9 months after start of glargine treatment."

Trial Locations (1)

Unknown

Sanofi-Aventis Administrative Office, Bromma